Zinc-enhanced therapy improves eradicationZinc carnosine-based modified bismuth quadruple therapy standard triple therapy for eradication: A randomized controlled study.
We explored the effectiveness of a modified bismuth quadruple therapy that includes zinc carnosine, in comparison to the traditional triple therapy for treating indigestion caused by Helicobacter pylori infection. In our study, 92 patients with symptoms of dyspepsia and positive breath tests were randomly assigned to receive either the conventional treatment of esomeprazole, amoxicillin, and clarithromycin for 14 days, or a shorter 10-day course of the new therapy that also included bismuth subcitrate and zinc carnosine.
The results were quite revealing. Our findings showed that the modified bismuth quadruple therapy group had a significantly higher eradication rate of 93.5%, compared to 69.6% in the standard treatment group. This suggests that the addition of zinc carnosine to the treatment regimen could enhance the effectiveness of indigestion relief. Importantly, the side effects reported between the two groups were similar, with only mild dizziness noted in those receiving the new therapy.
Overall, the study indicates that a shorter course of therapy that includes zinc carnosine may be a superior option for individuals suffering from indigestion related to Helicobacter pylori. This approach not only appears to work better but also does not lead to more serious side effects, making it an appealing alternative to traditional treatment methods.
Read More